Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine, Rituximab, and Alemtuzumab for Previously Treated B-CLL or SLL
NCT00143065Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Aug 2005
- Primary completion
- Feb 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Started Aug 2005; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00143065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143065.